Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 27;109(2):466–478. doi: 10.3324/haematol.2023.282897

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2024 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 1. — Sm-3’RRrec is detectable in chronic lymphocytic leukemia patients and Sm-3’RRrec counts are significantly increased in Sm-3’RRrec^High samples. (A) Sm-3’RR recombination (Sm-3’RRrec) junction counts analyzed by next-generation sequencing and CSReport in healthy volunteer peripheral blood mononuclear cells (PBMC) (N=9, 239 Sm-3’RRrec junctions) and chronic lymphocytic leukemia (CLL) patients, divided into 2 groups based on the mean of junction counts obtained in healthy PBMC: Sm-3’RRrecL^ow CLL (≤27 junctions per sample, N=35, 357 junctions) and Sm-3’RRrec^High CLL (>27 junctions per sample, N=12, 703 junctions). (B) Class switch recombination (CSR) junction counts were at comparable levels in both CLL groups (Sm-3’RRrec^Low: N=35, 22,247 junctions; Sm-3’RRrec^High: N=11, 10,739 junctions) and were lower than in HV PBMC (N=11, 27,528 junctions). Graphs represent the mean ± standard error of the mean. Statistical analyses were performed using unpaired t test. 3’RR: 3’ regulatory region; NS: not significant; **P<0.01; ***P<0.001.